3Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel Ⅲ [J]. Guidelines Cireulat, 2004,110: 227 - 239.
4Ssever P, Dahloef B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesteroal concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Ann (ASCOL-LLA) : a multicentre randomised controlled trial[J]. Lancet,2003,361:1149 - 1158.
5Cannon CP, I Braunwald E, McCabe C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med, 2004,350:1495 - 504.
6LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J]. N Engl J Med, 2005,352: 1425 - 3145.
7Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Third report of the national cholesterel education program (NCEP) expert panel on detection,evaluation and treatment of high blood cholesterol in adults final repert[J]. Circulation, 2002, 106:3143 - 3421.
8Newman CB, Palmer G, Silbershatz, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients [J]. Am J Cardiol, 2003, 92:670-676.
9Staffa JA, Chang J, Green L. Cefivastatin and reports of fatal rhabdomyolysis[J] . N Engl J Med, 2002, 346. 539- 540.
10Holdass H, Fellstrom B, Jardine AG, et al. On behalf of the assessment of lescol in renal transplantation study investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial [J]. Lancet, 2003, 361:2024- 2031.
